• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Carson William H.

    6/14/23 4:42:11 PM ET
    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DBTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Carson William H.

    (Last) (First) (Middle)
    C/O DECIBEL THERAPEUTICS, INC.
    1325 BOYLSTON STREET, SUITE 500

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Decibel Therapeutics, Inc. [ DBTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/13/2023 A 5,000(1) A $0.00 5,000(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $4.78 06/13/2023 A 5,000 (3) 06/12/2033 Common Stock 5,000 $0.00 5,000 D
    Explanation of Responses:
    1. Consists of shares of the Issuer's common stock issuable under 5,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest in full on the one year anniversary of the date of grant of the RSUs (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the RSUs), subject to the reporting person's continued service.
    2. Includes 5,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting.
    3. This option was granted on June 13, 2023 for 5,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service.
    Remarks:
    Exhibit Index: 24.1 Power of Attorney
    /s/ Jeffrey Schulz, Attorney-in-Fact 06/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DBTX

    DatePrice TargetRatingAnalyst
    3/15/2023$7.00 → $2.00Outperform → Market Perform
    SVB Securities
    12/2/2021$25.00Buy
    JonesTrading
    11/15/2021$23.00Buy
    HC Wainwright & Co.
    11/10/2021$15.00 → $14.00Outperform
    SVB Leerink
    10/22/2021$21.00Outperform
    Robert W. Baird
    10/22/2021$21.00Outperform
    Baird
    More analyst ratings

    $DBTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Trask Anna returned 106,864 shares to the company, closing all direct ownership in the company

      4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)

      9/25/23 4:35:59 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Carson William H. returned 5,000 shares to the company, closing all direct ownership in the company

      4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)

      9/25/23 4:32:58 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lee John Jui-Jen returned 147,144 shares to the company, closing all direct ownership in the company

      4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)

      9/25/23 4:30:31 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Decibel Therapeutics downgraded by SVB Securities with a new price target

      SVB Securities downgraded Decibel Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $7.00 previously

      3/15/23 7:30:18 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JonesTrading initiated coverage on Decibel Therapeutics with a new price target

      JonesTrading initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $25.00

      12/2/21 8:42:59 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Decibel Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $23.00

      11/15/21 6:07:44 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DBTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Decibel Therapeutics Inc.

      15-12G - Decibel Therapeutics, Inc. (0001656536) (Filer)

      10/10/23 4:56:54 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Decibel Therapeutics Inc.

      EFFECT - Decibel Therapeutics, Inc. (0001656536) (Filer)

      10/10/23 12:15:13 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Decibel Therapeutics Inc.

      S-8 POS - Decibel Therapeutics, Inc. (0001656536) (Filer)

      9/25/23 9:09:56 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

      - Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing

      5/15/23 7:45:00 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

      BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. "We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Matt's appointment to the Board provides us with a critical strategic perspective, as we continue to build Decibel and lead

      3/21/23 7:00:34 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

      - Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the CHORD™ trial in the First Half of 2023 - - Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate - BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial result

      3/14/23 4:05:00 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG

      NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Western Asset Mortgage Capital Corporation (NYSE:WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed merger, WMC shareholders will receive 1.5 shares of AG Mortgage Investment Trust, Inc. for each share of WMC common stocked owned and a cash payment from Angelo Gordon equal to approximately 9.99% of the aggregate per share merger consideration (not to exceed $7 million in total). If you are a WMC investor, and would like additional information about our investigation, please complete the Information R

      8/12/23 8:17:00 PM ET
      $CTG
      $DBTX
      $MITT
      $WMC
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

      - Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financi

      8/11/23 7:45:00 AM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

      Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Decibel Therapeutics, Inc. (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of

      8/9/23 7:30:53 AM ET
      $DBTX
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Decibel Therapeutics Inc. (Amendment)

      SC 13G/A - Decibel Therapeutics, Inc. (0001656536) (Subject)

      2/14/24 4:55:24 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Decibel Therapeutics Inc. (Amendment)

      SC 13D/A - Decibel Therapeutics, Inc. (0001656536) (Subject)

      9/27/23 4:05:18 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Decibel Therapeutics Inc.

      SC 13D - Decibel Therapeutics, Inc. (0001656536) (Subject)

      8/18/23 5:16:09 PM ET
      $DBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care